Continued treatment with sotorasib for KRAS G12C cancer
Treatments studied
Part of Cancer clinical trials.
This study is for people who are already taking the targeted therapy sotorasib (with or without another drug called panitumumab) in an Amgen clinical trial and are still doing well. It lets you keep receiving the same treatment after your original study ends, so you don't have to stop a medicine that is working for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You are currently taking sotorasib (Lumakras) in an Amgen research study and it is still helping you.
- You have not permanently stopped sotorasib before your previous study ended.
- You are able to swallow pills and keep a daily medication diary.
- You are generally well enough to be up and about (ECOG performance status 0-2).
- If you could become pregnant, you agree to use birth control during the study and for a period after your last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies sotorasib, a targeted medicine, in people with non-small cell lung cancer (NSCLC) that has a specific KRAS mutation called G12C. You may be eligible if your cancer has spread or can’t be removed by surgery and has grown again after at least one previous treatment.
This trial tests a new drug (BAY3498264) combined with sotorasib, a targeted therapy, for people with advanced cancers that have a specific genetic change called KRAS G12C. It's for those who have already tried other treatments and need new options.
This trial tests an oral targeted drug called sotorasib for people with a specific type of advanced lung cancer (KRAS G12C mutation) who have not had any prior treatment for their advanced disease. It aims to see if this drug can shrink tumors and help patients without using standard chemotherapy or immunotherapy first.
This Phase 2 study tests sotorasib (also called AMG510) in people with Stage III lung cancer that cannot be removed by surgery and that has a specific KRAS mutation (p.G12C). You may be able to join if you cannot safely receive chemo-radiotherapy at the same time, and the study checks whether sotorasib can help shrink or control the cancer.
This study tests a new targeted drug called sotorasib combined with standard chemotherapy for people with advanced pancreatic cancer that has a specific KRAS G12C mutation. The goal is to see if the combination works better than chemotherapy alone.
This trial tests a combination of two targeted drugs (panitumumab and sotorasib) with a common IV chemo (5-fluorouracil) as a first treatment for people with a specific type of advanced colorectal cancer who cannot tolerate stronger chemo. It offers a gentler option that may be more effective than standard care.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.